Please provide your email address to receive an email when new articles are posted on . Union rate did not differ between patients who received allograft, autograft or no biologic adjuvant during foot ...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot ...

The views, opinions and product experiences discussed in this article, whether implicit or explicit, are those of Dr. McCormick and do not necessarily reflect the views and opinions of Stryker. Proper ...

ZURICH, SWITZERLAND / ACCESSWIRE / January 4, 2024 / Kuros Biosciences, a leader in next generation bone graft technologies, announced today three advancements related to its MagnetOs portfolio of ...

Please provide your email address to receive an email when new articles are posted on . Results showed no significant differences in retear rates between patients with vs. those without tendinopathy.

In the past couple of years there have been numerous changes made to the code sets for reporting arthrodesis techniques, instrumentation and bone grafts versus biomechanical devices so let’s review ...

Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Schlieren (Zürich), Switzerland, Decemb ...